市場調査レポート
商品コード
1589029

腫瘍/がんマーカーの世界市場

Tumor / Cancer Markers
表紙：腫瘍/がんマーカーの世界市場

出版日
ページ情報
英文 114 Pages
納期
即日から翌営業日
適宜更新あり
腫瘍/がんマーカーの世界市場
出版日: 2024年11月13日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 114 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

腫瘍/がんマーカーの世界市場は2030年までに65億米ドルに到達

2023年に42億米ドルと推定される腫瘍/がんマーカーの世界市場は、2023年から2030年にかけてCAGR 6.5%で成長し、2030年には65億米ドルに達すると予測されます。

米国市場は11億米ドル、中国はCAGR 10.6％で成長予測

米国の腫瘍/がんマーカー市場は2023年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに15億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは10.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と6.8%と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界の腫瘍/がんマーカー市場- 主要動向と促進要因のまとめ

腫瘍・がんマーカーは早期発見と治療にどのような革命をもたらしているか？

腫瘍マーカーおよびがんマーカーは、様々ながんの早期発見、診断、管理に関する重要な洞察を提供し、現代の腫瘍学において不可欠なものとなっています。これらのマーカーは、がん患者の血液、尿、組織中にしばしば高濃度で検出される物質であり、腫瘍の存在と進行を同定する上で重要な役割を果たしています。腫瘍マーカーは、タンパク質、ホルモン、その他の分子物質であり、がん細胞自体またはがんに反応して体内で産生されます。腫瘍マーカーは、前立腺がん、卵巣がん、肝臓がん、乳がんなど、特定の種類のがんを検出するのに特に有用です。これらのマーカーによる早期発見は、早期介入や個別化された治療戦略を可能にすることで、予後を大幅に改善することができます。診断的役割に加え、がんマーカーは治療効果のモニタリングや再発の検出にも使用され、ペイシェントジャーニー全体を通じて不可欠なツールとなっています。プレシジョン・メディシンの台頭により、腫瘍マーカーは患者固有の生物学的構造に基づいて治療法を調整するためにますます使用されるようになっており、がんへのアプローチ方法に革命をもたらしています。

どのような技術の進歩が腫瘍マーカーやがんマーカーの使用を促進しているのか？

最近の技術進歩により、腫瘍マーカーやがんマーカーの同定と応用が大幅に強化され、診断と治療の両面でその有用性が拡大しています。次世代シークエンシング（NGS）などの分子生物学的手法の向上により、がんの発生に寄与する遺伝子変異や変化の詳細な解析が可能になった。これにより、特定の種類のがんに特異的な新しいバイオマーカーが発見され、より正確な発見と診断が可能になった。リキッドバイオプシーも重要な技術革新であり、臨床医は侵襲的な組織生検ではなく、簡単な血液サンプルで腫瘍マーカーを検出できます。この非侵襲的アプローチは、循環腫瘍DNA（ctDNA）やその他のマーカーの検出を可能にし、患者のがんの状態をリアルタイムで把握し、治療反応のモニタリングや再発の早期兆候の発見を容易にします。免疫組織化学（IHC）と酵素結合免疫吸着測定法（ELISA）の進歩により、腫瘍マーカーレベルの測定に使用される検査の感度と特異度が向上し、より正確な結果が得られるようになった。さらに、人工知能（AI）と機械学習のがん診断への統合は、複雑なデータセットを分析し、より正確な予後につながるパターンを特定するのに役立っています。これらのテクノロジーは、がんの同定だけでなく、個別化された治療計画を導き、患者の転帰を改善するためにも、腫瘍マーカーの使用方法の限界を押し広げつつあります。

なぜ腫瘍マーカーとがんマーカーはヘルスケア提供者の間で重要性を増しているのか？

腫瘍マーカーとがんマーカーは、比較的迅速かつ正確に患者のがんの状態に関する重要な洞察を提供できるため、ヘルスケアプロバイダーの間で重要性が増しています。がんが依然として世界の主要死因の1つであることから、早期発見ツールの需要が急増しており、腫瘍マーカーはその最前線にあります。ヘルスケアプロバイダーは、腫瘍マーカーを初期診断だけでなく、病気の進行や治療効果のモニタリングにも活用しています。例えば、前立腺特異抗原（PSA）検査は前立腺がんのスクリーニングに広く用いられており、CA-125は卵巣がんのモニタリングによく用いられています。がん治療を受けている患者にとって、腫瘍マーカーは治療に対する体の反応をリアルタイムでフィードバックし、治療の適時調整を可能にします。さらに腫瘍マーカーは、治療後のがんの再発リスクを評価する上で不可欠な役割を果たします。このように長期にわたってがんを追跡・管理する能力は、特にがんが再発する前に何年も休眠状態にあるようなケースでは極めて重要です。より多くの種類のがんマーカーが発見されるにつれ、ヘルスケアプロバイダーはこれらの検査を日常的ながん治療に取り入れるようになっています。

腫瘍・がんマーカー市場の成長を促す要因は何か？

腫瘍・がんマーカー市場の成長は、いくつかの重要な要因によって牽引されており、それぞれが腫瘍学の分野を再構築しています。最も重要な促進要因の1つは、世界のがん罹患率の上昇であり、これにより早期発見とより効果的な治療戦略に対する需要が高まっています。人口の高齢化と生活習慣に関連した危険因子の増加に伴い、腫瘍マーカーのような信頼性の高い診断ツールの必要性がかつてないほど高まっています。さらに、リキッドバイオプシーやゲノムシークエンシングを含む分子診断学の進歩は、早期発見と継続的ながん管理の両方において腫瘍マーカーを使用する新たな可能性を開いています。ヘルスケアプロバイダーが、個々の患者に存在する特定の生物学的マーカーに基づいてがん治療をカスタマイズしようとする傾向が強まっているためです。このような個別化アプローチは、治療効果を高めるだけでなく、患者の遺伝子プロファイルに合わせて治療を調整することで不必要な副作用を軽減します。腫瘍学の研究開発の拡大も新たなバイオマーカーの発見につながっており、これらのバイオマーカーは臨床診療に組み込まれつつあるため、腫瘍マーカー検査の需要はさらに高まっています。最後に、がんの早期発見の重要性に関する一般市民の意識の高まりと、がん検診プログラムを改善する政府の取り組みが、ヘルスケアシステム全体における腫瘍マーカー検査の幅広い採用を後押ししています。このような動向の進展に伴い、腫瘍・がんマーカー市場は大きく成長し、がん治療の将来において極めて重要な役割を果たすと予想されます。

調査対象企業の例（全84件）

  • 20/20 Genesystems, Inc.
  • Abbott Diagnostics
  • AC Immune SA
  • Acuamark Diagnostics
  • Advanced Cell Diagnostics, Inc.
  • Affimedix, Inc.
  • Agilent Technologies, Inc.
  • Alere, Inc.
  • Alexion Pharmaceuticals, Inc.
  • ARUP Laboratories

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP17898

Global Tumor / Cancer Markers Market to Reach US$6.5 Billion by 2030

The global market for Tumor / Cancer Markers estimated at US$4.2 Billion in the year 2023, is expected to reach US$6.5 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 10.6% CAGR

The Tumor / Cancer Markers market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Tumor / Cancer Markers Market - Key Trends and Drivers Summarized

How Are Tumor and Cancer Markers Revolutionizing Early Detection and Treatment?

Tumor and cancer markers have become indispensable in modern oncology, providing critical insights into the early detection, diagnosis, and management of various cancers. These markers, which are substances often found in higher levels in the blood, urine, or tissue of people with cancer, play a crucial role in identifying the presence and progression of tumors. Tumor markers can be proteins, hormones, or other molecular substances produced either by the cancer cells themselves or by the body in response to cancer. They are particularly useful in detecting specific types of cancers, such as prostate, ovarian, liver, and breast cancer. Early detection through these markers can significantly improve outcomes by allowing for earlier interventions and personalized treatment strategies. In addition to their diagnostic role, cancer markers are also employed in monitoring the effectiveness of treatments and detecting recurrences, making them vital tools throughout a patient’s cancer journey. With the rise of precision medicine, tumor markers are increasingly being used to tailor treatment options based on a patient's unique biological makeup, revolutionizing how cancer is approached.

What Technological Advancements Are Driving the Use of Tumor and Cancer Markers?

Recent technological advancements have greatly enhanced the identification and application of tumor and cancer markers, expanding their utility in both diagnostics and treatment. Improvements in molecular biology techniques, such as next-generation sequencing (NGS), have enabled the detailed analysis of genetic mutations and alterations that contribute to cancer development. This has led to the discovery of new biomarkers that are specific to certain types of cancers, allowing for more precise detection and diagnosis. Liquid biopsy is another significant innovation, allowing clinicians to detect tumor markers through a simple blood sample rather than invasive tissue biopsies. This non-invasive approach enables the detection of circulating tumor DNA (ctDNA) and other markers, providing a real-time view of a patient’s cancer status and making it easier to monitor treatment response and detect early signs of recurrence. Advances in immunohistochemistry (IHC) and enzyme-linked immunosorbent assays (ELISA) have improved the sensitivity and specificity of tests used to measure tumor marker levels, ensuring more accurate results. Additionally, the integration of artificial intelligence (AI) and machine learning into cancer diagnostics is helping to analyze complex datasets and identify patterns that can lead to more accurate prognoses. These technologies are pushing the boundaries of how tumor markers are used, not only in identifying cancers but also in guiding personalized treatment plans and improving patient outcomes.

Why Are Tumor and Cancer Markers Gaining Importance Among Healthcare Providers?

Tumor and cancer markers are gaining increasing importance among healthcare providers because of their ability to provide crucial insights into a patient’s cancer status with relative speed and accuracy. As cancer remains one of the leading causes of death globally, the demand for early detection tools has surged, and tumor markers are at the forefront of this shift. Healthcare providers rely on tumor markers not just for initial diagnoses but also for monitoring the progression of the disease and the effectiveness of treatments. For instance, the prostate-specific antigen (PSA) test is widely used to screen for prostate cancer, while CA-125 is often used to monitor ovarian cancer. In patients undergoing cancer therapy, tumor markers can offer real-time feedback on how well the body is responding to treatment, allowing for timely adjustments in therapy. Moreover, tumor markers play an essential role in assessing the risk of cancer recurrence after treatment. This ability to track and manage cancer over time is critical, especially in cases where cancer may remain dormant for years before returning. As more types of cancer markers are discovered, healthcare providers are increasingly incorporating these tests into routine cancer care, thus improving the personalization of treatment and leading to better overall patient management.

What Factors Are Driving the Growth of the Tumor and Cancer Marker Market?

The growth in the tumor and cancer marker market is being driven by several key factors, each of which is reshaping the field of oncology. One of the most significant drivers is the rising global incidence of cancer, which has created a growing demand for early detection and more effective treatment strategies. As the population ages and lifestyle-related risk factors increase, the need for reliable diagnostic tools like tumor markers has never been more critical. Additionally, advances in molecular diagnostics, including liquid biopsies and genomic sequencing, have opened up new possibilities for using tumor markers in both early detection and ongoing cancer management. The shift toward precision medicine is another major factor driving market growth, as healthcare providers increasingly seek to customize cancer treatments based on the specific biological markers present in individual patients. This personalized approach not only improves the effectiveness of treatments but also reduces unnecessary side effects by tailoring therapies to the patient's genetic profile. The expansion of research and development in oncology has also led to the discovery of new biomarkers, which are being integrated into clinical practice, further fueling the demand for tumor marker testing. Finally, increasing public awareness about the importance of early cancer detection, along with government initiatives to improve cancer screening programs, is supporting the broader adoption of tumor marker tests across healthcare systems. As these trends continue to evolve, the tumor and cancer marker market is expected to grow significantly, playing a pivotal role in the future of cancer care.

Select Competitors (Total 84 Featured) -

  • 20/20 Genesystems, Inc.
  • Abbott Diagnostics
  • AC Immune SA
  • Acuamark Diagnostics
  • Advanced Cell Diagnostics, Inc.
  • Affimedix, Inc.
  • Agilent Technologies, Inc.
  • Alere, Inc.
  • Alexion Pharmaceuticals, Inc.
  • ARUP Laboratories

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Tumor / Cancer Markers - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Incidence of Cancer Expands Market Opportunity for Tumor and Cancer Markers
    • Growing Focus on Early Cancer Detection Propels Demand for Tumor Marker Testing
    • Technological Advancements in Biomarker Discovery Drive Growth in Cancer Diagnostics
    • Here's How Precision Medicine Accelerates Demand for Specific Tumor Markers in Targeted Therapies
    • Rising Use of Liquid Biopsies Strengthens the Business Case for Non-Invasive Cancer Marker Testing
    • Increasing Adoption of Personalized Cancer Treatment Plans Expands the Role of Tumor Markers
    • Advances in Genomic and Proteomic Technologies Propel Innovation in Cancer Marker Development
    • Growing Prevalence of Companion Diagnostics Generates Demand for Tumor Marker-Based Tests
    • Rising Awareness of Preventive Oncology Boosts Demand for Early-Stage Cancer Marker Detection
    • Expanding Use of AI and Big Data Analytics in Cancer Marker Analysis Propels Growth
    • Growing Focus on Minimally Invasive Testing Strengthens Adoption of Tumor Markers in Routine Screening
    • Here's How the Development of Multimodal Biomarker Panels Expands Opportunities for Comprehensive Cancer Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Tumor / Cancer Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Tumor / Cancer Markers Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • CHINA
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Tumor / Cancer Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Tumor / Cancer Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • INDIA
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Tumor / Cancer Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Tumor / Cancer Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR

IV. COMPETITION